Cellromax Science Co., Ltd. (KOSDAQ:471820)
South Korea
· Delayed Price · Currency is KRW
5,300.00
+20.00 (0.38%)
At close: Apr 29, 2026
Cellromax Science Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
| Market Capitalization | 58,296 | 73,574 | 57,231 |
| Market Cap Growth | 11.25% | 28.56% | - |
| Enterprise Value | 51,070 | 68,367 | - |
| Last Close Price | 5280.00 | 6435.26 | 4704.43 |
| PE Ratio | 20.23 | 24.80 | 14.99 |
| PS Ratio | 2.63 | 3.32 | 2.65 |
| PB Ratio | 1.24 | 1.57 | 1.29 |
| P/TBV Ratio | 1.32 | 1.67 | 1.39 |
| P/FCF Ratio | 34.16 | 43.11 | 9.40 |
| P/OCF Ratio | 32.65 | 41.21 | 9.09 |
| EV/Sales Ratio | 2.30 | 3.08 | - |
| EV/EBITDA Ratio | 15.41 | 20.63 | - |
| EV/EBIT Ratio | 18.01 | 24.11 | - |
| EV/FCF Ratio | 29.92 | 40.06 | - |
| Debt / Equity Ratio | 0.01 | 0.01 | 0.03 |
| Debt / EBITDA Ratio | 0.14 | 0.14 | 0.25 |
| Debt / FCF Ratio | 0.28 | 0.28 | 0.25 |
| Net Debt / Equity Ratio | -0.15 | -0.15 | -0.48 |
| Net Debt / EBITDA Ratio | -2.18 | -2.18 | -3.58 |
| Net Debt / FCF Ratio | -4.23 | -4.23 | -3.49 |
| Asset Turnover | 0.44 | 0.44 | - |
| Inventory Turnover | 2.14 | 2.14 | - |
| Quick Ratio | 3.08 | 3.08 | 7.41 |
| Current Ratio | 5.20 | 5.20 | 9.10 |
| Return on Equity (ROE) | 6.49% | 6.49% | - |
| Return on Assets (ROA) | 3.54% | 3.54% | - |
| Return on Invested Capital (ROIC) | 6.27% | 7.74% | 17.55% |
| Return on Capital Employed (ROCE) | 5.90% | 5.90% | 12.00% |
| Earnings Yield | 5.09% | 4.03% | 6.67% |
| FCF Yield | 2.93% | 2.32% | 10.64% |
| Payout Ratio | 114.25% | 114.25% | - |
| Buyback Yield / Dilution | -9.27% | -9.27% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.